COMP <GO>
VTRS vs INSM // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Viatris Inc. (NASDAQ) VS. Insmed Incorporated (NASDAQ) • 15-METRIC TALLY: VTRS 7
— INSM 5
■ METRIC PARITY
LAST: $19.04 (-0.86%) • MKT CAP: $21.86B
options-implied-move
—
LAST: $112.58 (+0.89%) • MKT CAP: $24.70B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VTRS VS. INSM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VTRS | INSM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.20% | 79.70% | -44.50 | INSM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -8.10% | -35.00% | +26.90 | VTRS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 8.78% | -3.97% | +12.75 | VTRS | /fcf-yield <GO> |
| Operating Margin | -18.70% | -60.00% | +41.30 | VTRS | /operating-margins <GO> |
| Net Profit Margin | -14.60% | -60.00% | +45.40 | VTRS | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 66.70% | -69.70 | INSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.81 | 5.25 | -4.44 | INSM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | VTRS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.5 | 62.2 | +0.30 | VTRS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.03 | +0.12 | VTRS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 21.0x | +12.00 | INSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $21.86B | $24.70B | -$2.83B | INSM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VTRS REV | INSM REV | VTRS GROSS % | INSM GROSS % | VTRS FCF | INSM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.25B | $606.4M | 35.2% | 79.7% | $1.94B | -$967.6M |
| FY 2024 | $14.69B | $363.7M | 38.3% | 76.4% | $1.98B | -$705.8M |
| FY 2023 | $15.39B | $305.2M | — | — | $2.21B | -$550.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VTRS // BETA 1.15
INSM // BETA 1.03